Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDI Reducing Reliance On Top Pharma Clients

This article was originally published in The Pink Sheet Daily

Executive Summary

Contract sales organization’s top four clients – AstraZeneca, GSK, Novartis and Sanofi-Aventis – will represent 59% of 2005 revenue, versus 81% in 2004, PDI says. Contracts with three of the four companies have been renewed.

You may also be interested in...



Sanofi-Aventis Ends PDI Sales Contract

Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.

Sanofi-Aventis Ends PDI Sales Contract

Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.

AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says

The sales and marketing staffing firm currently contracts 800 reps to AstraZeneca.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel